Alzheimer's disease (AD) is a common neurodegenerative disorder affecting more than 3 million people in the United States. AD etiology is only partially understood. Four genes have been implicated in the inheritance of AD and additional genes remain to be identified. Recently, we and others studying frontotemporal dementia (FTD), found causative mutations in the gene encoding tau. Tau is the main protein of neurofibrillary tangles (NFT's) that are found in both AD and FTD. Other variants of tau pathology are also found in FTD (e.g glial fibrillary tangles). The FTD mutations demonstrate that genetic alterations in tau cause both neurodegeneration and tau pathology, that in some cases closely parallels the changes observed in AD. Thus, tau appears to be an active participant in neurodegenerative events and tau pathology is not just a secondary consequence of AD changes. Different tau mutations cause FTD by different mechanisms; in some cases, the biochemical properties of tau are altered while for other mutations, splicing of exon 10 appears to be altered. Mutations that affect splicing appear to act by 3 mechanisms; some affect the 5'splice site of exon 10, others alter exon splicing enhancer (ESE) regulatory elements, and at least one alters an exon splicing silencer. One goal of this proposal is to understand how the tau gene is regulated in normal and disease cells. First, the genomic sequence of the mouse and human tau gene will be determined and compared to identify conserved non-repeat sequences. Conserved regions are potential cis-acting regulatory elements. Second, the role of these conserved sequences in the regulation of normal splicing will be determined. Third, the mechanism by which polymorphisms and FTD mutations affect this splicing will be determined. We have identified over 30 tau polymorphisms in normal subjects and many of these are in potential regulatory sequences. A fourth goal is to evaluate the role of tau variants in AD. AD subjects will be screened for causative mutations as well as mutations that affect progression. A fifth goal is to refine the location of additional AD loci using Monte Carlo simulation methods for analysis of family data.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG011762-09
Application #
6509599
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Miller, Marilyn
Project Start
1994-06-01
Project End
2003-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
9
Fiscal Year
2002
Total Cost
$232,602
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Ryman, Davis C; Acosta-Baena, Natalia; Aisen, Paul S et al. (2014) Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83:253-60
Kay, D M; Stevens, C F; Hamza, T H et al. (2010) A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2. Neurology 75:1189-94
Melrose, H L; Dächsel, J C; Behrouz, B et al. (2010) Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 40:503-17
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38
Wijsman, Ellen M; Sung, Yun Ju; Buil, Alfonso et al. (2007) Summary of Genetic Analysis Workshop 15: Group 9 linkage analysis of the CEPH expression data. Genet Epidemiol 31 Suppl 1:S75-85
Sieh, Weiva; Yu, Chang-En; Bird, Thomas D et al. (2007) Accounting for linkage disequilibrium among markers in linkage analysis: impact of haplotype frequency estimation and molecular haplotypes for a gene in a candidate region for Alzheimer's disease. Hum Hered 63:26-34
D'Souza, Ian; Schellenberg, Gerard D (2006) Arginine/serine-rich protein interaction domain-dependent modulation of a tau exon 10 splicing enhancer: altered interactions and mechanisms for functionally antagonistic FTDP-17 mutations Delta280K AND N279K. J Biol Chem 281:2460-9
Wijsman, Ellen M; Daw, E Warwick; Yu, Xuesong et al. (2005) APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 132B:14-20
Wijsman, Ellen M; Daw, E Warwick; Yu, Change-En et al. (2004) Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am J Hum Genet 75:398-409

Showing the most recent 10 out of 28 publications